Abstract
Background Arthritogenic alphaviruses such as chikungunya (CHIKV) and o’nyong-nyong (ONNV) viruses have shown capacity to cause widespread epidemics, with recurrent and sporadic outbreaks occurring throughout sub-Saharan Africa.
Methods We analyzed the seroprevalence for CHIKV and ONNV in 470 non-febrile subjects from three regions in Senegal (Sindia, 2018; Thies, 2018; and Kedougou, 2022/2023) using retrospective samples. We assessed the presence of anti-CHIKV IgG and neutralizing antibody titers against CHIKV and ONNV via enzyme-linked immunosorbent assay (ELISA) and microneutralization tests, respectively, and determined risk factors of CHIKV and ONNV exposure by binary logistic regression.
Results The overall alphavirus seroprevalence based on an anti-CHIKV viral like particle (VLP) IgG ELISA was 38.5%, with rates varying geographically: Kedougou (48.6%), Thies (31.9%), and Sindia (14.9%). Neutralizing antibody titers revealed CHIKV and ONNV seroprevalence rates of 7.4% and 9.8%, respectively, with significant variations by region and age group. Cross-reactivity analysis showed that 82.9% of CHIKV cases exhibited a neutralizing response to ONNV, while 71.7% of ONNV cases cross-neutralized CHIKV. Residents of Thies had significantly higher odds of CHIKV infection (aOR, 3.147; 95% CI: 1.164-8.510) while ONNV infection was more likely in Kedougou (aOR, 3.888; 95% CI: 1.319-11.466). Furthermore, older age (> 40 years) was a significant risk factor both CHIKV (aOR, 2.094; 95% CI: 0.846-5.185) and ONNV infection (aOR, 2.745; 95% CI: 1.212-6.216).
Conclusions Our study confirms the co-circulation of CHIKV and ONNV in Senegal, highlighting their geographic and demographic distribution. These findings underscore the need for continued surveillance, alphavirus testing, and tailored public health strategies to mitigate their impact in Senegal.
Competing Interest Statement
BBH is a co-founder of Mir Biosciences, Inc., a biotechnology company that develops diagnostics and vaccines for infectious diseases, cancer, and autoimmunity.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The samples included in our study were originally collected as part of malaria and non-malarial surveillance among residents of Thies, Sindia, and Kedougou, Senegal. Samples from Thies and Sindia were part of the surveillance of non-malarial febrile illnesses, while samples from Kedougou were part of genomic surveillance of malaria. Informed consent was obtained from all subjects and/or their legal guardians for the initial sample collection as well as for its future use. All methods were performed in accordance with the guidelines and regulations set forth by the Declaration of Helsinki. The primary studies under which the samples and data were collected received ethical clearance from the CIGASS Institutional Review Board (IRB) (Protocol numbers: SEN15/46, 19300, and SEN14/49). All excess samples and corresponding data were banked and de-identified prior to the analyses. This study received and exemption determination from the Rutgers Robert Wood Johnson Medical School IRB.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵4 Laboratoire d’ecologie vectorielle et parasitaire
We revised the manuscript to include prevalence rates stratified by age groups, geographical locations, and gender. We also updated the seroprevalence rates by representing against the total population rather than the subgroup of ELISA positives.
Data Availability
Data produced as part of the current study are available in the manuscript or upon request from the corresponding author.
